Affimed NV (AFMD) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Leerink Partners Maintains Affimed NV(AFMD.US) With Buy Rating, Cuts Target Price to $5
Moomoo News13:31 ET · Ratings
H.C. Wainwright Maintains Affimed NV(AFMD.US) With Buy Rating, Maintains Target Price $7
Moomoo NewsDec 19 05:33 ET · Ratings
Truist Financial Maintains Affimed NV(AFMD.US) With Buy Rating
Moomoo NewsDec 19 05:33 ET · Ratings
H.C. Wainwright Maintains Affimed NV(AFMD.US) With Buy Rating, Cuts Target Price to $7
Moomoo NewsDec 18 06:35 ET · Ratings
Express News | Affimed NV : H.c. Wainwright Cuts Target Price to $7 From $10
ReutersDec 18 06:17 ET
Wells Fargo Maintains Affimed NV(AFMD.US) With Buy Rating, Cuts Target Price to $11
Moomoo NewsDec 17 21:31 ET · Ratings

Comments

Jaguar8

Dec 9 12:35

NEWS

$Affimed NV (AFMD.US)$
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
▪️AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the highest dose level (300 mg) in heavily pretreated R/R AML patients
▪️AFM28 demonstrates a favorable safety profile: Grade 1 and 2 Infusion related reactions (IRRs) were the main related side effect...

2

This_Guy

Dec 8 17:23

$Affimed NV (AFMD.US)$
🤔
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
Positive
High overall response rate of 86% in heavily pretreated patients
Complete response rate of 55% in patients with treatment options
Well-managed safety profile with no unexpected safety signals
Successful validation of treatment in multi-center setting
Negative
None.

3

Trytosaveabit

Dec 8 15:39

Watching 12/9/24 PR / New data released 12//8

$Affimed NV (AFMD.US)$ Affimed Announced at ASH Meeting, Combination Of Acimtamig With AlloNK Demonstrated An Overall Response Rate Of 86%; Complete Response Of 55% In 22 Heavily Pretreated Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Who Have Exhausted All Standard Of Care Treatments
Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announc...

1

Jaguar8

Dec 8 11:00

NEWS SUNDAY 12/8

$Affimed NV (AFMD.US)$
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
Sunday, 8th December at 12:00 pm
The combination of acimtamig with AlloNK® demonstrated an overall response rate of 86% and complete response of 55% in 22 heavily pretreated patients with R/R cHL, who have exhausted all standard of care treatments
The combination showed a well-managea...

1

Jaguar8

Dec 8 02:14

🟢Watchlist December 9 Monday. Trading a stock is YOUR DECISION and you should be SOLELY ACCOUNTABLE for it. NFA.

$MSP Recovery (LIFW.US)$ Ticker change to MSPR Monday to consolidate services. Even with negative profit margin, of note, company had $10M settlements from property and casualty insurers and acquired Medicare claims valued $10.6B. Low float. Currently trading above 10/20 EMA suggesting short term bullishness. SI 162%, 0 shares LTB
$Roth CH Acquisition V Co(Delisted) (ROCL.US)$ Ticker change tomorr...

51

25

6

AFMD Affimed NV

Trade Overview

Capital Trend

News

Comments